Company Products (7) Management (10) Looking for (1)
 
  [print]   [close]
ADETHERAPEUTICS INC
BIOTECHGATE BY VENTURE VALUATION
Latest up-date: 21 Nov 2012
GENERAL INFORMATION
G
P
T
F
M
D
 
see on map
see on map
#19-410 Downey Road
Innovation Place Research Park
S7N 4N1 Saskatoon
Canada, Saskatchewan
close
Contact person Mr. Sanj Singh, President & CEO
Company main phone +1 (306) 2615189
E-mail [available with subscription]
Website www.adetherapeutics.com
 
Founded (year) 2006
Source of foundation Independent foundation
No. of employees
At this location
7
No. of R&D employees
At this location
5
Corporate description / mission
AdeTherapeutics is a privately-held clinical-stage drug development company. The company's vision is to be leader in developing products that deal with complications related to surgery. AdeTherapeutics has a robust portfolio of high value products by developing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages (i.e. Phase II trials). Lead indication is in adhesion prevention in gyne and general surgery in Phase 1/2 trial. Additional products are in neurosurgery, cosmetic surgery and wound care.
State of ownership Private / independent
Headquarters Yes
CATEGORIZATION
G
P
T
F
M
D
 
Main sector Biotechnology - Therapeutics and Diagnostics
Subsector(s)
  • Molecular diagnostics
  • Peptides
Primary therapeutic area(s)
  • Diseases of the eye
  • Skin and subcutaneous tissue
  • Musculoskeletal system and connective tissue
  • External causes of morbidity and mortality
 
Business model
  • In-licensing
  • Out-licensing
  • R&D
Customer segments
  • Small biotech
SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES
G
P
T
F
M
D
 
No. of Biotech Products Pre-clinical Phase I Phase II Phase III On the market
  3 1 1 n/a n/a
No. of Medtech Products In development       On the market
  2       n/a
Description of products
Lead indication is in the gyne/general surgical market for the prevention of adhesion formation. The product is a therapeutic using a highly safe dipeptide which can be used in all types of surgeries and easily delivered in open and scope surgeries. Spinal surgery program has begun lead by Stanford and Cleveland Clinic trained neurosurgeon. Recently added top glaucoma surgeon to develop anti-fibrosis following ophthalmology procedures.
KEY
G
General profile
P
Products
T
Technologies
F
Financing rounds
M
Management
D
Deals		  
 
Click here to update this profile >>
© 2013 Venture Valuation  |  Impressum  |  Terms of Use & Privacy Policy  |  Print